

Advertisement



[Home](#) > [News](#) > [Industry](#) > [Pharma News](#) > [Dr Reddys ropes in...](#) >

Dr Reddys Ropes In Penny Wan As Additional Director



By **Ruchika** — Published On 29 Jan 2022 1:24 PM | Updated On 29 Jan 2022 1:24 PM





Hyderabad: Drug major, Dr Reddy's Labs, has recently announced the appointment of Penny Wan as an Additional Director, categorized as Independent, on the Board of the company for a term of five consecutive years, effective January 28, 2022.

Penny Wan was most recently Amgen's Vice President of the Japan and Asia Pacific region. With over 20 years of experience in the biopharmaceuticals industry, she led Amgen's geographic expansion efforts in the region. Since joining the Company in 2014, she has been instrumental in building Amgen's commercial presence across the region, ensuring that innovative medicines reach patients, payers and physicians in these markets.

Prior to Amgen, Wan was General Manager of Roche Pharma China, which became one of the fastest growing multinational corporations in the Country. She spearheaded innovative partnership solutions with government, professional and patient groups to improve access and outcomes for patients. Wan also worked in the pharmaceuticals division of Wyeth, where she held various management, marketing and commercial positions in the US, Hong Kong, and Taiwan.

During her time in China, Wan served as an executive committee member of DPAC (R&D based Pharmaceutical Association Committee), where she led the industry-shaping efforts in biologics and served as Vice President of the Shanghai Association of Enterprises with Foreign Investments. She received the 2013 White Magnolia Memorial Award from the Shanghai municipality in recognition of her contributions to the city.

Penny brings deep experience across healthcare. She has comprehensive management experience and strategic skills in leading sales and marketing, manufacturing, business development, start-up, country and regional operations in

Penny is a confident, articulate executive with a strong presence. She has been hands-on executive and attributes her success to understanding science, handpicking the team, resource allocation and savvy business judgments. Additionally, Penny has worked across multiple sectors in pharma, infant formula, nutrition, vaccines, immunology, oncology, cardiovascular, bone and mental health, etc.

Penny holds a Graduate Diploma in business administration from Monash University & Chinese University of Hong Kong and a Bachelor of Science in Biochemistry and Pharmacology from Monash University of Australia.

Read also: [Ex-Sanofi MD Rajaram Narayanan appointed as SeQuent Scientific MD, CEO](#)



dr reddy's labs

dr reddy's labs news

pennv wan

appointment

amgen

roche pharma

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Ruchika

Ruchika joined Medical Dialogue as a Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health



News, Pharma News, Healthcare and Investment. She is a graduate from Delhi University. She can be contacted at editorial@medicdialogues.in Contact no. 011-43720751

Similar Posts

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our [Cookie Policy](#) and [Cookie Settings](#).

Justify dose modification criteria for anti-cancer drug: Authority tells GSK

Zydus Cadila starts supply of COVID-19 vaccine to govt

Pfizer, BioNTech begin rolling submission for EUA for COVID vaccine kids below 5

Pfizer, Ionis Pharma discontinue Vupanorsen Clinical Development Program

Merck COVID drug Molnupiravir last choice for US patients: Report

Anti-parasite drug Ivermectin shows antiviral effect against COVID: Japanese company

Lupin, Axantia collaborate for Pegfilgrastim

Zydus Wellness net profit rises 1239.08 percent in Q3

DoP invites third round of applications for leftover slots under PLI Scheme

Alembic Pharma Clarithromycin tablets get USFDA okay

Issues of Medical Devices Industry did not get a highlight in Union Budget , says AiMeD

Roche gets USFDA nod for injectable eye medicine Vabysmo



- Email: info@medicaldialogues.in
- Phone: 011 - 4372 0751

Follow us on



Website Last Updated On : 1 Feb 2021 9:13 AM GMT

Company

[About Us](#)

[Contact Us](#)

[Our Team](#)

[Reach our Editor](#)

[Feedback](#)

[Submit Article](#)

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our [Cookie Policy](#) and [Cookie Settings](#).



[Advertise](#)

[Advertise Policy](#)

[Terms and Conditions](#)

[Privacy Policy](#)

[Editorial Policy](#)


[Comments Policy](#)

[Disclaimer](#)



This site complies with the HONcode standard for trustworthy health information: [verify here.](#)

Download Medical Dialogues App



Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our **expert team**, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our [terms of use](#), [privacy policy](#), [advertisement policy](#). You can check out disclaimers [here](#). © 2021 Minerva Medical Treatment Pvt Ltd

© 2021 - Medical Dialogues. All Rights Reserved.

Powered By: Hocalwire



We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our [Cookie Policy](#) and [Cookie Settings](#).